about
Gene therapy on the moveMolecular Determinants of Vectofusin-1 and Its Derivatives for the Enhancement of Lentivirally Mediated Gene Transfer into Hematopoietic Stem/Progenitor Cells.Vectofusin-1, a new viral entry enhancer, strongly promotes lentiviral transduction of human hematopoietic stem cells.Concurrent measures of fusion and transduction efficiency of primary CD34+ cells with human immunodeficiency virus 1-based lentiviral vectors reveal different effects of transduction enhancersEngraftment and in vivo proliferation advantage of gene corrected mobilized CD34(+) cells from Fanconi anemia patients."RCL-Pooling Assay": A Simplified Method for the Detection of Replication-Competent Lentiviruses in Vector Batches Using Sequential Pooling.Lentiviral-Mediated Gene Therapy in Fanconi Anemia-A Mice Reveals Long-Term Engraftment and Continuous Turnover of Corrected HSCs.Improvement of De Novo Cholesterol Biosynthesis Efficiently Promotes the Production of Human Immunodeficiency Virus Type 1-Derived Lentiviral Vectors.Vectofusin-1, a Potent Peptidic Enhancer of Viral Gene Transfer forms pH-dependent α-Helical Nanofibrils, Concentrating Viral Particles.Peptides derived from evolutionarily conserved domains in Beclin1 and Beclin2 enhance the entry of lentiviral vectors into human cells.Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult.Lymphopoiesis in transgenic mice over-expressing Artemis.Treatment of Uveitis by In Situ Administration of Ex Vivo-Activated Polyclonal Regulatory T Cells.Non-Clinical Efficacy and Safety Studies on G1XCGD, a Lentiviral Vector for Ex Vivo Gene Therapy of X-Linked Chronic Granulomatous Disease.Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemiaToward a Scalable Purification Protocol of GaLV-TR-Pseudotyped Lentiviral VectorsVectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System ManufacturingBiosafety Studies of a Clinically Applicable Lentiviral Vector for the Gene Therapy of Artemis-SCIDTemporary Reduction of Membrane CD4 with the Antioxidant MnTBAP Is Sufficient to Prevent Immune Responses Induced by Gene Transfer
P50
Q27007012-1981794A-D5F7-4B92-A5AF-8F78660B4B58Q36518267-1EDF0FB0-3C7A-48DC-B0C6-F54823C7ACD8Q36757162-EC6AFC66-94E5-4341-BF96-1D31A6FCB09CQ37633922-1E3387A9-BF36-45B0-BFC1-8E7793EF6B3CQ38628205-A07D222F-0044-401A-8F22-060B257CB86FQ38793398-12628105-A3B8-47C3-BBCA-D6F1ED3FA766Q38831800-EAE1E64A-6EEC-4317-90EE-9CFA3163B507Q40388659-05094D89-A893-44CA-981A-0A8D21837497Q41919808-CE8D3600-62CA-4331-B8F0-F725593535ADQ41934341-A7EADCCE-9040-4EEE-ADC0-DA74E3118038Q45869832-B710F898-ABAD-49CE-A661-07BF09E4C67EQ45879168-213A6B81-1E47-471A-9DFF-D35792EABDCFQ46602988-22205F23-7F5E-49C6-91CD-C507C0573E62Q52319062-5F457326-B455-4482-B02C-763E9893FFD2Q90003769-BC02928B-0FC4-4E2F-BC24-D0BBDBE1C57FQ90085943-11024DF3-66B1-472B-8F28-A1012E18735BQ90444691-6CFFD5EC-9208-4EBF-9A35-DA879805D757Q91262690-8A33FAC7-C6B6-4310-86EF-4CEDDF298D88Q93190169-8E2C9864-7473-4E96-B7A7-6AB45BAB4461
P50
description
investigador
@es
researcher
@en
name
Anne Galy
@en
type
label
Anne Galy
@en
prefLabel
Anne Galy
@en
P108
P31
P496
0000-0002-0153-4392